• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

NCCN Unveils Value Tool for CML and MM

Article

NCCN Evidence Blocks add affordability to Guidelines recommendations on safety, efficacy, quality, and consistency of regimens.

At its 10th Annual Congress on Hematological Malignancies, the National Comprehensive Cancer Network (NCCN) provided details of the NCCN Evidence Blocks for chronic myelogenous leukemia (CML) and multiple myeloma (MM). The announcement of this value calculator had created ripples back in August when it followed the release of ASCO’s Value Framework and the DrugAbacus tool developed by Peter Bach, MD, and his team at the Memorial Sloan Kettering Cancer Center.

"NCCN Evidence Blocks will educate providers and patients about the efficacy, safety, and affordability of systemic therapy, serving as a starting point for shared decision-making based on the individual patient's value system," said Robert W. Carlson, MD, chief executive officer, NCCN.

Read the press release.

Related Videos
Amit Singal, MD, UT Southwestern Medical Center
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Beau Raymond, MD
Video 15 - "Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion"
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Raajit Rampal, MD, PhD, screenshot
Ronesh Sinha, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Yuqian Liu, PharmD
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.